These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1299 related articles for article (PubMed ID: 28461123)

  • 1. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
    Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Ikezoe K; Sokai A; Nakatsuka Y; Taguchi Y; Hatta K; Noma S; Kobashi Y; Yoshizawa A; Oga T; Hirai T; Chin K; Nagai S; Izumi T; Mimori T; Mishima M
    Respir Med; 2017 Jun; 127():57-64. PubMed ID: 28461123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
    Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
    Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics of patients with anti-aminoacyl-tRNA synthetase antibody positive idiopathic interstitial pneumonia.
    Yura H; Sakamoto N; Satoh M; Ishimoto H; Hanaka T; Ito C; Hasegawa T; Tanaka S; Miyamura T; Nakashima S; Hara A; Kakugawa T; Oda K; Kido T; Obase Y; Ishimatsu Y; Yatera K; Kawakami A; Mukae H
    Respir Med; 2017 Nov; 132():189-194. PubMed ID: 29229096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: a retrospective case control study.
    Hozumi H; Enomoto N; Kono M; Fujisawa T; Inui N; Nakamura Y; Sumikawa H; Johkoh T; Nakashima R; Imura Y; Mimori T; Suda T
    PLoS One; 2015; 10(3):e0120313. PubMed ID: 25789468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition?
    Lega JC; Cottin V; Fabien N; Thivolet-Béjui F; Cordier JF
    J Rheumatol; 2010 May; 37(5):1000-9. PubMed ID: 20231208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China.
    Zhan X; Yan W; Wang Y; Li Q; Shi X; Gao Y; Ye Q
    BMC Pulm Med; 2021 Feb; 21(1):57. PubMed ID: 33579248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
    Yoshida N; Okamoto M; Kaieda S; Fujimoto K; Ebata T; Tajiri M; Nakamura M; Tominaga M; Wakasugi D; Kawayama T; Kuwana M; Mimori T; Ida H; Hoshino T
    Respir Investig; 2017 Jan; 55(1):24-32. PubMed ID: 28012490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical value of myositis antibodies in patients with connective tissue disease-associated interstitial lung diseases].
    Xie MM; Zou RY; Li Y; Liu Y; Chen LL; Liu XQ; Zhao Q; Ding JJ; Chen ZY; Cai HR
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Oct; 42(10):765-770. PubMed ID: 31594111
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of usefulness in surfactant protein D as a predictor of mortality in myositis-associated interstitial lung disease.
    Kaieda S; Gono T; Masui K; Nishina N; Sato S; Kuwana M;
    PLoS One; 2020; 15(6):e0234523. PubMed ID: 32525903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of cytokine profiles between anti-ARS antibody-positive interstitial lung diseases and those with anti-MDA-5 antibodies.
    Asakawa K; Yoshizawa K; Aoki A; Kimura Y; Tanaka T; Ohashi K; Hayashi M; Kikuchi T; Sato S; Takada T
    Clin Rheumatol; 2020 Jul; 39(7):2171-2178. PubMed ID: 32056068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies.
    Yoshifuji H; Fujii T; Kobayashi S; Imura Y; Fujita Y; Kawabata D; Usui T; Tanaka M; Nagai S; Umehara H; Mimori T
    Autoimmunity; 2006 May; 39(3):233-41. PubMed ID: 16769657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics of dermatomyosits/polymyositis associated interstitial lung disease according to the autoantibody.
    Kishaba T; McGill R; Nei Y; Ibuki S; Momose M; Nishiyama K; Nagano H; Yamashiro S
    J Med Invest; 2018; 65(3.4):251-257. PubMed ID: 30282869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis.
    Matsushita T; Hasegawa M; Fujimoto M; Hamaguchi Y; Komura K; Hirano T; Horikawa M; Kondo M; Orito H; Kaji K; Saito Y; Matsushita Y; Kawara S; Yasui M; Seishima M; Ozaki S; Kuwana M; Ogawa F; Sato S; Takehara K
    J Rheumatol; 2007 May; 34(5):1012-8. PubMed ID: 17309126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for the recurrence of interstitial lung disease in patients with polymyositis and dermatomyositis: a retrospective cohort study.
    Nakazawa M; Kaneko Y; Takeuchi T
    Clin Rheumatol; 2018 Mar; 37(3):765-771. PubMed ID: 28975463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary manifestations of anti-ARS antibody positive interstitial pneumonia--with or without PM/DM.
    Takato H; Waseda Y; Watanabe S; Inuzuka K; Katayama N; Ichikawa Y; Yasui M; Fujimura M
    Respir Med; 2013 Jan; 107(1):128-33. PubMed ID: 23137883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival and outcomes after lung transplantation for connective tissue disease-associated interstitial lung diseases.
    Yang X; Wei D; Liu M; Wu B; Zhang J; Xu H; Ye S; Liu F; Hu C; Chen J
    Clin Rheumatol; 2021 Sep; 40(9):3789-3795. PubMed ID: 33755837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies.
    Chen F; Li S; Wang T; Shi J; Wang G
    Am J Med Sci; 2018 Jan; 355(1):48-53. PubMed ID: 29289262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome.
    Lega JC; Fabien N; Reynaud Q; Durieu I; Durupt S; Dutertre M; Cordier JF; Cottin V
    Autoimmun Rev; 2014 Sep; 13(9):883-91. PubMed ID: 24704867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
    Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
    J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome.
    Hamaguchi Y; Fujimoto M; Matsushita T; Kaji K; Komura K; Hasegawa M; Kodera M; Muroi E; Fujikawa K; Seishima M; Yamada H; Yamada R; Sato S; Takehara K; Kuwana M
    PLoS One; 2013; 8(4):e60442. PubMed ID: 23573256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.